üFirst in class, nucleoshuttling HDACi
üHigh efficacy in vitro and in vivo (tumor growth inhibition at less than 2mM)
üLow toxicity compared to pan-HDACis
üMetabolically stable – avoids clearance of drug to allow for complete and prolonged effectiveness
üMinimal to no CYP enzyme inhibition – low chance of unanticipated adverse effects and therapeutic failure
üAbility to improve other anticancer agents offers prospects for development in combination with other Pharma drugs